Covance and Indiana Clinical and Translational Sciences Institute to conduct early clinical trials
Two organisations will conduct high-quality research in a safe and regulated environment for sponsors who are looking to recruit both healthy volunteers and patients
US-based drug development services company Covance and the Indiana Clinical and Translational Sciences Institute (CTSI), part of the Indiana University (IU) School of Medicine, are to collaborate in conducting early clinical trials for new medicines on behalf of biotechnology and pharmaceutical companies.
This alliance provides a significant opportunity to bring more Phase I clinical research to Indiana, through the clinical research unit located within the IU School of Medicine in Indianapolis and Covance’s clinical research unit located in Evansville. Phase I clinical research includes studies where investigational new drugs are administered to humans for the first time.
Working together, the two organisations will conduct high-quality research in a safe and regulated environment for sponsors who are looking to recruit both healthy volunteers and patients for early clinical studies.
‘The alliance with the Indiana CTSI will help us provide biopharmaceutical clients with quicker access to patients in a hospital setting that supports specialised care and monitoring,’ said Rob Aspbury, Vice President and General Manager, Global Clinical Pharmacology Services at Covance. ‘With quicker access to patients, we can streamline the drug development process and bring important new medications to patients who need them.’